CoChat

Unobserved “Home” Induction Onto Buprenorphine

Lee, Joshua D., Vocci, Frank, Fiellin, David A. · 2014 · Journal of Addiction Medicine
Cited by 58

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Unobserved, or "home" buprenorphine induction is common in some clinical practices. Patients take the initial and subsequent doses of buprenorphine after, rather than during, an office visit. This review summarizes the literature on the feasibility and acceptability, safety, effectiveness, and prevalence of unobserved induction. METHODS: We searched the English language literature for studies describing unobserved buprenorphine induction and associated outcomes. Clinical studies were assessed by strength of design, bias, and internal and external validity. Surveys of provider practices and unobserved induction adoption were reviewed for prevalence data and key findings. We also examined previous review papers and international buprenorphine treatment guidelines. RESULTS: N = 10 clinical studies describing unobserved induction were identified: 1 randomized controlled trial, 3 prospective cohort studies, and 6 retrospective cohort studies. The evidence supports the feasibility of unobserved induction, particularly in office-based primary care practices. Evidence is weak to moderate in support of no differences in adverse event rates between unobserved and observed inductions. There is insufficient or weak evidence in terms of any or no differences in overall effectiveness (treatment retention, medication adherence, illicit opioid abstinence, other drug use). N = 9 provider surveys assessed unobserved induction: observed induction logistics are seen as barriers to buprenorphine prescribing; unobserved induction appears widespread in specific locations. International guidelines reviewed emphasize clinician or pharmacist observed induction (the United States, the United Kingdom, France, Australia); only one (Denmark) explicitly endorses unobserved induction. CONCLUSIONS: There is insufficient evidence supporting unobserved induction as more, less, or as effective as observed induction. However, the predominantly observational and naturalistic studies of unobserved induction reviewed, all of which have significant sources of bias and limited external validity, document feasibility and low rates of adverse events. Unobserved induction seems to be widely adopted in US and French regional provider surveys. Prescribers, policy makers, and patients should balance the benefits of observed induction such as maximum clinical supervision with the ease-of-use and comparable safety profile of unobserved induction.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/adm.0000000000000059

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 27

  1. Albright, 2010, Psychiatrist characteristics that influence use of buprenorphine medication-assisted treatment., J Addict Med, 4, 197, 10.1097/ADM.0b013e3181c816f3 · DOI
  2. Alford, 2007, Treating homeless opioid dependent patients with buprenorphine in an office-based setting., J Gen Intern Med, 22, 171, 10.1007/s11606-006-0023-1 · DOI · Paper page
  3. Cunningham, 2011, A comparison of buprenorphine induction strategies: patient-centered home-based inductions versus standard-of-care office-based inductions., J Subst Abuse Treat, 40, 349, 10.1016/j.jsat.2010.12.002 · DOI · Paper page
  4. Cunningham, 2007, Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians., J Gen Intern Med, 22, 1325, 10.1007/s11606-007-0264-7 · DOI
  5. Doolittle, 2011, A case series of buprenorphinenaloxone treatment in a primary care practice., Subst Abus, 32, 262, 10.1080/08897077.2011.599256 · DOI
  6. Egan, 2010, The physician clinical support system-buprenorphine (PCSS-B): a novel project to expandimprove buprenorphine treatment., J Gen Intern Med, 25, 936, 10.1007/s11606-010-1377-y · DOI · Paper page
  7. Fiellin, 2004, Consensus statement on office-based treatment of opioid dependence using buprenorphine., J Subst Abuse Treat, 27, 153, 10.1016/j.jsat.2004.06.005 · DOI
  8. Gibson, 2003, A comparison of buprenorphrine treatment in clinic and primary care settings: a randomised trial., Med J Aust, 179, 38, 10.5694/j.1326-5377.2003.tb05417.x · DOI · Paper page
  9. Gunderson, 2011, Buprenorphine induction: a major barrier for physician adoption of office-based opioid dependence treatment., J Addict Med, 5, 304, 10.1097/ADM.0b013e31821ee8fe · DOI
  10. Gunderson, 2006, Evaluation of a combined online and in person training in the use of buprenorphine., Subst Abus, 27, 39, 10.1300/J465v27n03_06 · DOI
  11. Gunderson, 2010, Unobserved versus observed office buprenorphinenaloxone induction: a pilot randomized clinical trial., Addict Behav, 35, 537, 10.1016/j.addbeh.2010.01.001 · DOI
  12. Kissin, 2006, Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence., J Addict Dis, 25, 91, 10.1300/J069v25n04_09 · DOI · Paper page
  13. Lee, 2009, Home buprenorphinenaloxone induction in primary care., J Gen Intern Med, 24, 226, 10.1007/s11606-008-0866-8 · DOI
  14. Lee, 2012, Buprenorphine-naloxone maintenance following release from jail., Subst Abus, 33, 40, 10.1080/08897077.2011.620475 · DOI
  15. Lintzeris, 2002, A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal., Addiction, 97, 1395, 10.1046/j.1360-0443.2002.00215.x · DOI · Paper page
  16. Lucas, 2010, Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: a randomized trial., Ann Intern Med, 152, 704, 10.7326/0003-4819-152-11-201006010-00003 · DOI
  17. Moher, 2009, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement., J Clin Epidemiol, 62, 1006, 10.1016/j.jclinepi.2009.06.005 · DOI · Paper page
  18. Moore, 2007, Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients., J Gen Intern Med, 22, 527, 10.1007/s11606-007-0129-0 · DOI · Paper page
  19. Netherland, 2009, Factors affecting willingness to provide buprenorphine treatment., J Subst Abuse Treat, 36, 244, 10.1016/j.jsat.2008.06.006 · DOI · Paper page
  20. Soeffing, 2009, Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year., J Subst Abuse Treat, 37, 426, 10.1016/j.jsat.2009.05.003 · DOI
  21. Sohler, 2010, Home- versus office-based buprenorphine inductions for opioid-dependent patients., J Subst Abuse Treat, 38, 153, 10.1016/j.jsat.2009.08.001 · DOI · Paper page
  22. Stein, 2005, Buprenorphine retention in primary care., J Gen Intern Med, 20, 1038, 10.1111/j.1525-1497.2005.0228.x · DOI · Paper page
  23. Thomas, 2008, Use of buprenorphine for addiction treatment: perspectives of addiction specialists and general psychiatrists., Psychiatr Serv, 59, 909, 10.1176/ps.2008.59.8.909 · DOI
  24. Turner, 2005, Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence., Arch Intern Med, 165, 1769, 10.1001/archinte.165.15.1769 · DOI
  25. Vignau, 2001, Practice-based buprenorphine maintenance treatment (BMT): how do French healthcare providers manage the opiate-addicted patients J Subst Abuse T, reat, 21, 135
  26. Walley, 2008, Office-based management of opioid dependence with buprenorphine: clinical practices and barriers., J Gen Intern Med, 23, 1393, 10.1007/s11606-008-0686-x · DOI · Paper page
  27. Whitley, 2010, Factors associated with complicated buprenorphine inductions., J Subst Abuse Treat, 39, 51, 10.1016/j.jsat.2010.04.001 · DOI

Cited by

See all 58

Metadata

Authors
Lee, J. D., Vocci, F., & Fiellin, D. A.
Venue
Journal of Addiction Medicine
Published
2014-09
Volume
8
Issue
5
Pages
299-308
ISSN
1932-0620 (ISSN-L)
OpenAlex
W2064271499
Cited by
58
References
6
FWCI
2.76
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Unobserved “Home” Induction Onto Buprenorphine. https://app.cochat.ai/papers/10.1097/adm.0000000000000059
The paper
Lee, J. D., Vocci, F., & Fiellin, D. A. (2014). Unobserved “Home” Induction Onto Buprenorphine. Journal of Addiction Medicine. https://doi.org/10.1097/adm.0000000000000059

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.